You've reached your goal weight on Mounjaro — what comes next?

You've hit the number on the scales, but your biology hasn't changed

Here's the honest version of this moment, which our prescribers hear about most weeks: reaching goal weight feels like an endpoint, but physiologically it isn't. The reason Mounjaro worked is that tirzepatide damps the hormonal signals that drive hunger and increases fullness after meals, via both GIP and GLP-1 receptor pathways, and you can read a full breakdown of what happens when you take Mounjaro and why those mechanisms matter. Those underlying signals don't disappear when you hit a target number. They're structural, and for most people they reassert themselves once the medicine is reduced or removed.

Trial data makes this plain. In the SURMOUNT-1 programme, participants who stopped tirzepatide after the active phase and moved to placebo regained a substantial portion of the weight they had lost over the following months. That isn't a failure of willpower; it's a documented physiological response to removing a medicine that was doing a specific job. The NHS patient information for tirzepatide is clear that this is a long-term weight management treatment, not a short course.

So when you reach goal weight, the first conversation with your prescriber is not automatically about stopping, and our dedicated guide to what happens when you reach your target weight on Mounjaro walks through exactly what that conversation typically covers. It's about what 'management' looks like from here: maintaining the current dose, reducing to the lowest dose that holds the result, or planning a careful wind-down with close monitoring. That conversation depends on your starting point, how long you've been on treatment, and what your broader health picture looks like. You can read more about what life looks like after Mounjaro for people who do choose to finish treatment.

Continuing at your maintenance dose: why this is often the right call

Mounjaro's UK licence covers weight management as an ongoing indication, not simply weight loss. That matters. Many people remain on their maintenance dose (10mg or 15mg for those who've titrated up) beyond goal weight, with the aim of holding the result rather than losing further. Your dose isn't automatically increased when you're at goal; it may even be reviewed downward if clinical signs support it.

NICE's appraisal of tirzepatide, TA1026, takes a long-term view of the medicine's use in obesity, which is itself a chronic condition. The clinical rationale for ongoing treatment at goal weight is the same as it is for any long-term medicine managing a chronic condition: the condition hasn't gone away, even if its most visible marker has improved.

Practically, this means your prescriber will want to review you regularly even when your weight is stable. At nume, every repeat order is clinically re-reviewed, there are no automatic renewals. If the evidence supports continuing, that's what the review will reflect. If your health picture has changed, the review will reflect that too. You can explore the wider context of how Mounjaro is used in UK weight management if you're still early in the process.

Reducing or stopping: how to do it safely

If you and your prescriber decide that stopping is the right move, stepping down gradually is generally preferable to stopping abruptly. There's no single approved tapering schedule written into the UK licence, so the approach is individualised, your prescriber leads it. What stepping down looks like in practice might mean extending the interval between pens, or dropping one dose tier at a time and holding for several weeks before reviewing weight stability.

The risk to plan for is rebound. Weight often begins returning within weeks of stopping, especially if lifestyle changes haven't been embedded. The honest question to ask before stopping is whether your eating habits, activity levels and sleep patterns are genuinely different from before treatment, not just different because the medicine is suppressing appetite. If those foundations are solid, the rebound is slower and more manageable. If they aren't yet, that's useful information for your prescriber, not a reason to avoid the conversation, but a reason to have it properly.

People who stop Mounjaro sometimes find the process less straightforward than they expected. Our guide to stopping Mounjaro covers what to expect in the weeks that follow, including what changes to watch for and when to contact your clinical team.

What you can do right now to protect what you've achieved

Whichever path your prescriber recommends, three things reliably help at the maintenance stage. First, protein intake matters more than most people realise; adequate protein during any weight-loss phase protects muscle mass, and continuing to prioritise it means the weight you're holding is the weight worth holding. Second, resistance activity (even two sessions a week) is the most evidence-supported behavioural lever for long-term weight maintenance. Third, sleep and stress patterns affect the very appetite hormones that Mounjaro acts on; poor sleep alone can undo several weeks of progress.

These aren't new pieces of advice, but they hit differently at goal weight, when the medicine is doing less of the heavy lifting. The NHS's healthy weight guidance sets out the evidence behind each of these in plain terms.

Cost is a practical reality at this stage too, if you're weighing up whether to continue private treatment, our overview of Mounjaro costs in the UK explains what a legitimate private prescription typically includes and what the market looks like after the 2025 list-price changes. Reaching goal weight is genuinely worth protecting. A few minutes with a prescriber reviewing your options is a sensible next step, start a free consultation with our clinical team if you'd like that conversation now.